Action Potential Venture Capitalapvcis A Venture Capital Fund Established By Glaxosmithkline In 2013Based In Cambridgemassachusettsapvc Invests In Companies That Are Pioneering Bioelectronic Medicines And Related Technologiesthe Fund Focuses On Leveraging Advances In Hardwarecomputingand Material Science To Develop Therapies That Regulate Neural Or Cellular Activityaiming To Treat Chronic Diseases More Effectively Apvc Takes An Active Role In Its Investmentsoften Participating On The Boards Of Start Ups To Guide Their Growththe Fund Emphasizes Creating A Diverse And Inclusive Workspaceextending This Commitment To The Companies It Supportsapvc Is Dedicated To Advancing Medical Technology And Fostering A Diverse Healthcare Investor And Entrepreneurial Community
